Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Allakos Inc chart...

About the Company

allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.

CEO

Robert Alexander

Exchange

NASDAQ

Website

http://www.allakos.com/

$M

Total Revenue

124

Employees

$115M

Market Capitalization

-0.67

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ALLK News

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4

2d ago, source:

Net Loss: Allakos Inc ( NASDAQ:ALLK) reported a net loss of $62.6 million in Q4 2023, widening from $43.0 million in Q4 2022. R&D Expenses: R&D expenses rose to $53.8 million in Q4 2023, up from $35.4 ...

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

4d ago, source:

General and administrative expenses were $11.2 million for the fourth quarter of 2023 compared to $10.8 million for the fourth quarter of 2022, an increase of $0.4 million. The quarter over quarter ...

Hold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 Developments

3d ago, source:

LifeSci Capital analyst Sam Slutsky has maintained their neutral stance on ALLK stock, giving a Hold rating today. Sam Slutsky has given his ...

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

22d ago, source: Stockhouse

Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells ...

Allakos Announces a Restructuring to Focus on Development of AK006

18d ago, source: ADVFN

Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to ...

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

15d ago, source: ADVFN

Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy ...

Allakos Inc. (ALLK) stock price, news, quote & history – Yahoo Finance

14d ago, source: Yahoo Finance

Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells ...

Allakos Inc (37Z.DU)

19d ago, source: Yahoo Finance

Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells ...

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

4d ago, source: Morningstar

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory ...

Allakos Inc.: Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

21d ago, source: Finanznachrichten

Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector ...

Allakos Inc.: Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

3d ago, source:

Allakos Inc. (the "Company") (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...